Operational since 2016, Effectorbio staff have developed a novel 25-mer therapeutic peptide drug targeting the MARCKS Phosphorylation Site domain (MPS). MARCKS is the most prominent cellular substrate for protein kinase C. Protein binds calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein, Studies of shown promising results and suppressing multiple human diseases including but not limited to cancer, asthma and pulmonary fibrosis. The firm's emphasis is on developing peptide-based therapeutics for the treatment of cancers: lung and kidney cancer
